Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis

BACKGROUND: The economic outcome research of approved tyrosine kinase inhibitors for treating the chronic phase of chronic myeloid leukemia in developing is scarce. The aim of this study was to assess the cost-effectiveness of dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Adel, Ahmad, Abushanab, Dina, Hamad, Anas, Abdulla, Mohammad, Izham, Mohamed, Yassin, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204580/
https://www.ncbi.nlm.nih.gov/pubmed/33887995
http://dx.doi.org/10.1177/10732748211001796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204580/
https://www.ncbi.nlm.nih.gov/pubmed/33887995
http://dx.doi.org/10.1177/10732748211001796

Ejemplares similares